Recent News

SOHO 2021: Does Prolonged Lenalidomide Maintenance Improve Survival After Transplant in Myeloma?

SOHO 2021: Update on BCMA-Directed CAR T-Cell Therapy for Resistant Myeloma

SOHO 2021: ICARIA-MM Update on Isatuximab-Based Therapy for Multiple Myeloma

SOHO 2021: Survival Update From MAIA Trial on Daratumumab-Based Therapy in Myeloma

DREAMM-2: Sustained Activity Reported With Belantamab Mafodotin-blmf in Resistant Myeloma

Bone-Directed Therapy in Myeloma: How Often Should Bisphosphonates Be Given?

COVID-19 and Novel Agents for Myeloma: From a Single Center in the Czech Republic

Relapse-Associated Genetic Alterations and Drug-Specific Resistance in Myeloma

FDA Brief: Orphan Drug Designation for Two Novel Multiple Myeloma Treatments

COVID-19 Vaccine Responses Among Patients With Multiple Myeloma

Initial Results From Cohort A of CARTITUDE-2: Ciltacabtagene Autoleucel for Progressive Myeloma

ICARIA-MM: Updated Results With Isatuximab-Based Therapy for Resistant Myeloma

BOSTON Trial: Survival Outcomes With Selinexor in Elderly Patients With Multiple Myeloma

Trends in Multiple Myeloma–Related Inpatient Mortality

Can an MRD-Adaptive Study Design Help to De-escalate Therapy for Multiple Myeloma?

Comparing Two Oral Doublet Regimens for Resistant Multiple Myeloma

FDA Issues Safety Alert for Use of Melphalan Flufenamide in Multiple Myeloma

Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma

Adding Daratumumab to Combination Therapy for Newly Diagnosed Multiple Myeloma

First-in-Human Trial of Bispecific IgG4 Antibody for Multiple Myeloma

FDA Approves Daratumumab and Hyaluronidase-fihj Combination Therapy for Multiple Myeloma

ASCT With Carfilzomib-Based Regimens in Newly Diagnosed Multiple Myeloma

EHA2021: ANDROMEDA Trial Update Supports Daratumumab-Based Therapy for AL Amyloidosis

ASCO2021: CARTITUDE-1 Update on Ciltacabtagene Autoleucel for Resistant Myeloma

EHA2021: MRD Negativity as Myeloma Treatment Endpoint for Maintenance Therapy

ASCO 2021: Early Trial Update of Teclistamab in Resistant Multiple Myeloma

FDA Brief: Teclistamab Receives Breakthrough Therapy Designation for Resistant Myeloma

EHA2021: Targeting BCMA in Early-Phase Study in Resistant Myeloma

ASCO 2021: Durvalumab-Based Therapy for Ultra-High–Risk Newly Diagnosed Myeloma

ASCO 2021: KarMMa Update of BCMA-Directed CAR T-Cell Therapy for Refractory Myeloma

EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma

EHA2021: MAIA Trial Update on Daratumumab-Based Therapy for Newly Diagnosed Myeloma

ASCO 2021: Interim Analysis of CASSIOPEIA Trial of Daratumumab Maintenance in Myeloma

ASCO 2021: Ixazomib Maintenance After HCT in High-Risk Multiple Myeloma

Final Evidence Report From ICER on Three Therapies Targeting BCMA for Myeloma

BCMA CAR T-Cell Therapy Granted Priority Review for Multiple Myeloma

Ixazomib, Lenalidomide, and Dexamethasone in Myeloma: Routine Clinical Practice Versus Clinical Trials

Selinexor-Based Triplet in Myeloma: Impact of Age and Frailty in BOSTON Trial

Combination of Novel Antimyeloma Prototype and Cyclopamine Under Study

Does the First COVID-19 Vaccine Dose Offer Protection for Patients With Multiple Myeloma?

Peritransplant Orthostatic Hypotension and Multiple Myeloma

Frailty-Guided Treatment Strategy for Newly Diagnosed Patients With Myeloma

Risk Factors for Bloodstream Infections and Early Mortality in Multiple Myeloma

Whole-Genome Sequencing May Offer Insights to Multiple Myeloma Precursor Conditions

AACR 2021: Synergistic Selinexor-Based Combinations and Companion Biomarkers in Myeloma

Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy

AACR 2021: Role of ROBO1 Receptor in Growth of Multiple Myeloma

Weekly Carfilzomib-Based Regimen in Resistant Myeloma: Phase II Trial

Novel Oral PIM Kinase Inhibitor Under Study in Resistant Multiple Myeloma

Newly Diagnosed Myeloma: Novel Scenario for Carfilzomib-Linked Thrombotic Microangiopathy

AACR 2021: Is Novel IKZF1/3 Degrader Active Against Multiple Myeloma?

Isatuximab/Pomalidomide/Dexamethasone in Myeloma: Is Prescreening Patients for Biomarkers Warranted?

ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma

Expert European Panel Provides Clinical Practice Guidelines for Multiple Myeloma

Use of Generic Pomalidomide in India for Resistant Multiple Myeloma

Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial

FDA Approves Isatuximab-irfc Combination Therapy for Multiple Myeloma

FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma